Study identifier:NIS-OBR-FAS-2007/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer
Breast Cancer
-
No
Fulvestrant
Female
200
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
Dendrix - Scientific Information Architecture
Characterize the demographic and clinical features, as well as the main treatment results, among patients with advanced breast cancer treated with fulvestrant in Brazil.
Location
Location
Sao Paulo, SP, Brazil
Location
Porto Alegre, RS, Brazil
Location
Recife, PE, Brazil
Location
Rio de Janeiro, RJ, Brazil
Arms | Assigned Interventions |
---|---|
1 Postmenopausal women with hormone-receptor positive, advanced breast cancer who have failed at least one previous endocrine therapy and who have been treated at any one of the participating centres with fulvestrant. | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.